Stay updated on Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page
- Check2 days agoChange DetectedThe page’s footer/revision version was updated (from 3.5.2 to 3.5.3) and the “Lung cancer” related topics section was (re)added/updated with MedlinePlus Genetics. These changes affect only site presentation/navigation rather than the clinical trial information itself.SummaryDifference0.1%

- Check9 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check16 days agoChange DetectedRemoved the disease label 'Lung cancer' and the related topics section 'MedlinePlus Genetics' from the page.SummaryDifference0.1%

- Check23 days agoChange DetectedLung cancer and MedlinePlus Genetics related topics were added.SummaryDifference0.1%

- Check38 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page now shows a new revision tag, v3.4.3, replacing the previous v3.4.2.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Metastatic NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Metastatic NSCLC Clinical Trial page.